Once-daily single tablet regimen of tenofovir/emtricitabine/efavirenz—Potent, safe and convenient approach to combined antiretroviral therapy
HIV & AIDS Review · 2011
DOI: 10.1016/j.hivar.2011.03.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV & AIDS Review, 2011. Verfasst von Magdalena M. Dabrowska. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
The widely recommended standard triple (combined) antiretroviral therapy (cART) involves use of a minimum of three molecules from at least two classes of antiretroviral drugs. The main goals of cART are to achieve and maintain virologic suppression and immunologic reconstitution, to minimize drug toxicity and to prevent development of opportunistic infections and selection of multidrug-resistant HIV strains. Reaching these goals using traditional regimens usually requires complicated combinations of different ARV drugs and significant pill burden. Single tablet regimen—triple cART formulation of tenofovir DF, emtricitabine and efavirenz provides new simple therapeutic option which allows maintaining of efficacy and improvement of patients’ adherence to therapy. This article presents a short review of its efficacy, safety and patient related outcomes in HIV-infection management.
Zitieren
APA
Dabrowska, M. M. (2011). Once-daily single tablet regimen of tenofovir/emtricitabine/efavirenz—Potent, safe and convenient approach to combined antiretroviral therapy. HIV & AIDS Review. https://doi.org/10.1016/j.hivar.2011.03.004
Vancouver
Dabrowska MM. Once-daily single tablet regimen of tenofovir/emtricitabine/efavirenz—Potent, safe and convenient approach to combined antiretroviral therapy. HIV & AIDS Review. 2011. doi:10.1016/j.hivar.2011.03.004
BibTeX
@article{Dabrowska2011,
author = {Dabrowska, Magdalena M.},
title = {Once-daily single tablet regimen of tenofovir/emtricitabine/efavirenz—Potent, safe and convenient approach to combined antiretroviral therapy},
journal = {HIV & AIDS Review},
year = {2011},
doi = {10.1016/j.hivar.2011.03.004}
}
EUVIMED